Latest Valuation News

Adavale Resources has reported assay results from 13 additional drillholes at its London-Victoria gold mine, confirming and expanding gold mineralisation beneath the historic open pit. The ongoing drilling program supports a larger mineralised system along the Parkes Thrust corridor, with promising metallurgical testwork and a planned resource update.

Dexus (ASX: DXS) has declared an estimated distribution of 17.7 cents per security for the six months ending 30 June 2026, marking a reduction from prior payouts as it balances income returns with strategic capital initiatives.

ClearView Wealth has lodged its Scheme Booklet with ASIC, outlining Zurich's $0.65-per-share takeover offer and setting the stage for a pivotal shareholder vote on 27 July 2026.

General Capital Limited posted record revenue growth of 18% to $26.76 million for FY26, driven by a 63% jump in loan receivables and a 34% rise in term deposits. The group declared a final dividend, reflecting confidence amid economic uncertainty and a positive credit rating upgrade for its finance subsidiary.

Whitefield Industrials delivered a $21.1 million net profit for FY2026, upheld its long-standing dividend track record, and outperformed its benchmark despite geopolitical tensions and market volatility.

SDI Limited shareholders voted overwhelmingly in favour of a $1.40 per share acquisition scheme by InnoXvest Dental, setting the stage for court approval and delisting.

IFM Global Infrastructure Fund has increased its holding in Atlas Arteria to over 40%, maintaining a final takeover offer of A$5.10 per security. Meanwhile, Atlas Arteria's independent directors continue to recommend rejecting the bid, targeting higher distributions and exploring asset sales including the Warnow Tunnel.

Centuria Capital Group launches a $300 million fully underwritten equity raise to accelerate its AI Factory pipeline via ResetData and expand its real estate and credit funds platform.

Hawk Resources Limited has had its HWKOB securities suspended from trading pending compliance with ASX Listing Rule 2.5, affecting only this class of securities.

Cynata Therapeutics (ASX: CYP) has had its trading suspension lifted immediately following the publication of results from its Phase 3 Osteoarthritis and Phase 2 Graft versus Host Disease clinical trials.

Dexus Convenience Retail REIT reports a 1.1% net valuation uplift for H1 2026 and increases its on-market buy-back target to 5% of securities, signalling confidence in its portfolio and capital management.

Dexus Industria REIT's portfolio valuation edged up by $3.2 million at mid-2026, while the REIT increased its securities buy-back target to 5%, signalling confidence amid stable industrial market conditions.